Biologic therapy for autoimmune diseases: an update

Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopryin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study

(2012) Hal M. Hoffman et al.   CLINICAL THERAPEUTICS

Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections

(2012) Anne Isvy et al.   JOINT BONE SPINE

Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up

(2012) Giuseppe Cianchini et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Golimumab — a new tool in the armoury against inflammatory arthritis

(2011) Zoe Ash et al.   ANNALS OF MEDICINE

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

(2011) J. M. Kremer et al.   ANNALS OF THE RHEUMATIC DISEASES

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

(2011) P. C. Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

(2011) J. B. Kuemmerle-Deschner et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-Term Therapy with Intravenous Immunoglobulin is Beneficial in Patients with Autoimmune Diseases

(2011) Gisele Zandman-Goddard et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases

(2011) Uriel Katz et al.   CURRENT PHARMACEUTICAL DESIGN

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

(2010) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

(2010) J. T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

(2010) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

(2010) Alexander So et al.   ARTHRITIS AND RHEUMATISM

Drug-induced lupus: An update

(2010) Uriel Katz et al.   AUTOIMMUNITY REVIEWS

Advances in drug therapy for systemic lupus erythematosus

(2010) Daniel J Wallace   BMC Medicine

Treatment of systemic lupus erythematosus with epratuzumab

(2010) Pawel Traczewski et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

(2010) R. F. van VOLLENHOVEN et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

(2010) Gert J.D. Bergman et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus

(2009) Yihong Yao et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

(2009) Shaye Kivity et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following Rituximab treatment in systemic lupus erythematosus

(2009) GW Tew et al.   LUPUS

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

(2008) R Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

(2008) Robert D. Inman et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, Ameliorates Joint Swelling in Established Monkey Collagen-Induced Arthritis

(2008) Yasushi Uchiyama et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN